Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Steenland, Kylea; d; * | Zhao, Lipingb; d | Goldstein, Feliciac; d | Cellar, Janetc; d | Lah, Jamesc; d | for the Alzheimer's Disease Neuroimaging Initiative
Affiliations: [a] Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA | [b] Department of Biostatistics, Rollins School of Public Health, Emory University, Atlanta, GA, USA | [c] Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA | [d] Emory Alzheimer's Disease Research Center, Emory University, Atlanta, GA, USA
Correspondence: [*] Correspondence to: Kyle Steenland, Emory University, Rollins School Public Health, 1518 Clifton Road, Atlanta, GA 30322, USA. E-mail: nsteenl@emory.edu.
Abstract: Most studies evaluating Alzheimer's disease (AD) biomarkers longitudinally have studied patients with mild cognitive impairment (MCI) who progress to AD; data on normal subjects are scarce. We studied which biomarkers best predict cognitive decline on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) among those with normal cognition at baseline, and derived cut points to predict decline. We studied 191 subjects in the Alzheimer's Disease Neuroimaging Initiative (ADNI) who had normal cognition at baseline, 2 + visits (mean follow-up 3.1 years), and data on neuropsychological tests, cerebrospinal fluid (CSF) biomarkers, and structural MRI. We used repeated measures linear regression of log ADAS-Cog on age, race, gender, education, APOE4 status, baseline biomarker values, and follow-up time; an interaction between biomarker and time assessed predictive power. Neuropsychological tests did not significantly predict ADAS-Cog decline, while both MRI variables and CSF biomarkers did; CSF markers were the strongest predictors. Optimal cut points for baseline CSF markers to distinguish decliners were < 220 pg/ml (Aβ42), ≥61 pg/ml (t-tau), ≥21 pg/ml (p-tau), ≥0.31 (t-tau/Aβ42), and ≥0.10 (p-tau/Aβ42). For progression to MCI/AD (n = 28), the best markers were t-tau, t-tau/Aβ42, and p-tau/Aβ42, with optimal cut points of 58, 0.31, and 0.08, respectively. The optimal cut points across all markers and cut points predicted decline in ADAS-Cog, as well as transition to MCI, with a 65% accuracy. Our findings support current models of AD progression and suggest it is feasible to establish biomarker criteria to predict cognitive decline in individuals with normal cognition. Larger studies will be needed to more accurately characterize optimal cut points.
Keywords: biomarkers, cerebrospinal fluid, cognition, mild cognitive impairment
DOI: 10.3233/JAD-2014-131343
Journal: Journal of Alzheimer's Disease, vol. 40, no. 3, pp. 587-594, 2014
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl